Skip to content
Inciteful Med

Exploring Curative Therapies: Stem Cell Transplant and Gene Therapy

Last updated:

Curative therapies for sickle cell disease include stem cell transplants from donors and newly approved gene therapies like Casgevy and Lyfgenia that use your own modified cells. Both procedures require intense chemotherapy but can effectively stop the disease and prevent severe pain crises.

Key Takeaways

  • • Allogeneic stem cell transplants are the most established cure for sickle cell disease, with the best results coming from matched sibling donors.
  • • Casgevy and Lyfgenia are newly FDA-approved gene therapies that use your own cells to produce healthy hemoglobin, eliminating the risk of Graft-Versus-Host Disease.
  • • The gene therapy process is demanding and can take up to a year, involving cell collection, high-dose chemotherapy, infusion, and a long hospital recovery.
  • • Because the conditioning chemotherapy used in these treatments almost always causes permanent infertility, discussing fertility preservation beforehand is crucial.

For decades, managing sickle cell disease (SCD) meant treating the symptoms rather than the cause. Today, there are curative options that can effectively “stop” the disease by providing the body with a source of healthy, non-sickling hemoglobin [1][2]. While these treatments offer a life-changing alternative to daily management, they are intense procedures that require careful consideration of the risks and benefits [3][4].

Allogeneic Stem Cell Transplant (HSCT)

An allogeneic hematopoietic stem cell transplant (HSCT) is the most established curative treatment for SCD [1]. It involves replacing your bone marrow with healthy stem cells from a donor [5].

  • The Gold Standard: The best results come from a matched-sibling donor—a brother or sister who has the same tissue type (HLA) and does not have sickle cell disease [1][6].
  • The Process: The healthy stem cells are collected from the donor, while you receive chemotherapy to wipe out your own sickled marrow. The donor’s cells are then infused into you [5].
  • Success Rates: In children, transplants from matched siblings have success rates higher than 90% [6][7].
  • The Main Risk: The biggest challenge is Graft-Versus-Host Disease (GVHD), where the donor’s immune cells attack your body [8]. This can range from mild skin rashes to life-threatening organ damage [9].

The New Frontier: Gene Therapy

In late 2023, the FDA approved the first two gene therapies for SCD in patients aged 12 and older with severe disease [10][11]. These are autologous treatments, meaning they use your own cells, which eliminates the risk of GVHD entirely [12][13].

Casgevy (Exa-cel)

Casgevy is the first-ever approved treatment to use CRISPR/Cas9 “genetic scissors” [10][14].

  • How it works: It edits your stem cells to turn off a “silencer” gene (BCL11A), which allows your body to start making fetal hemoglobin (HbF) again [15][16].
  • Effectiveness: In clinical trials, 97% of patients were free from severe pain crises for at least a year after treatment [15][17].

Lyfgenia (Lovo-cel)

Lyfgenia uses a different technology called a lentiviral vector to add a new, functional gene to your cells [11][18].

  • How it works: It adds a modified gene that produces an “anti-sickling” hemoglobin [19][20].
  • Effectiveness: Trials showed near-complete resolution of severe vaso-occlusive events [20][4].
  • Safety Note: Lyfgenia carries a “boxed warning” because some patients in early trials developed blood cancers. While it is unclear if the treatment caused this, lifelong monitoring is required [21][19].

The Process: What to Expect

The gene therapy “journey” is very demanding and can take up to a year [22].

  1. Cell Collection: Your stem cells are collected from your blood over several sessions and sent to a lab to be genetically modified [15].
  2. Conditioning (Chemotherapy): You must undergo high-dose chemotherapy (usually busulfan) in the hospital to clear out your old bone marrow [23][15].
  3. The Infusion: Your newly modified cells are infused back into your bloodstream through an IV [15].
  4. Recovery: You will spend weeks in the hospital in isolation while your new immune system grows [22].

Important Considerations

  • Infertility: The chemotherapy used in these procedures almost always causes permanent infertility. It is vital to discuss fertility preservation (like freezing eggs or sperm) before starting [24][25].
  • Long-Term Data: While sibling transplants have been done for decades, we only have a few years of data for gene therapies. We do not yet know how they will perform over 20 or 30 years [26][27].
  • Cost and Access: These therapies are among the most expensive in the world, costing between $2.2 million and $3.1 million [28][29]. They are currently only available at a limited number of specialized centers [30][22].

Frequently Asked Questions

What is the main difference between a stem cell transplant and gene therapy for sickle cell disease?
A stem cell transplant replaces your bone marrow with cells from a healthy donor, which carries a risk of your body rejecting the cells. Gene therapy uses your own genetically modified stem cells, which eliminates the risk of donor cell rejection.
How do the new gene therapies, Casgevy and Lyfgenia, work?
Casgevy uses CRISPR technology to edit your genes so your body produces fetal hemoglobin. Lyfgenia adds a modified gene to your cells that produces an anti-sickling hemoglobin to prevent severe pain crises.
What are the main risks of getting gene therapy or a stem cell transplant?
Both treatments require intense chemotherapy before the procedure, which can cause permanent infertility and requires a long hospital stay. Stem cell transplants also carry the risk of Graft-Versus-Host Disease, where the donor cells attack your body.
Will I be able to have children after sickle cell gene therapy?
The high-dose chemotherapy required before gene therapy or a stem cell transplant almost always causes permanent infertility. It is very important to discuss fertility preservation options, like freezing eggs or sperm, before starting treatment.
How long does the gene therapy process take?
The entire gene therapy journey can take up to a year. It involves multiple sessions to collect your stem cells, lab time to modify them, a hospital stay for chemotherapy and the cell infusion, and weeks of isolation while your immune system recovers.

Questions for Your Doctor

  • • Do I have a matched sibling donor available for a traditional bone marrow transplant?
  • • Can you explain the difference between the 'gene editing' used in Casgevy and the 'gene addition' used in Lyfgenia?
  • • What are the specific risks of the 'conditioning' chemotherapy (busulfan) required before these treatments?
  • • What options do I have for fertility preservation before starting a curative therapy?
  • • Is this hospital a 'Qualified Treatment Center' for the newly approved gene therapies?

Questions for You

  • • How do I feel about the trade-off between the high success rate of these therapies and the lack of 10- or 20-year safety data?
  • • Am I prepared for the 'patient journey' of gene therapy, which includes months of hospital visits and a long recovery period?
  • • How much do my current pain crises and hospitalizations impact my life, and does that make the risks of curative treatment worth it to me?
  • • What is my plan for support (family, work, finances) during the several months I will be undergoing treatment?

Want personalized information?

Type your question below to get evidence-based answers tailored to your situation.

References

  1. 1

    Debating the Future of Sickle Cell Disease Curative Therapy: Haploidentical Hematopoietic Stem Cell Transplantation vs. Gene Therapy.

    Kassim AA, Leonard A

    Journal of clinical medicine 2022; (11(16)) doi:10.3390/jcm11164775.

    PMID: 36013014
  2. 2

    Gene Therapies for Sickle Cell Disease.

    Weaver SB, Singh D, Wilson KM

    The Journal of pharmacy technology : jPT : official publication of the Association of Pharmacy Technicians 2024; (40(5)):236-247 doi:10.1177/87551225241268742.

    PMID: 39391326
  3. 3

    Curative therapy for hemoglobinopathies: an International Society for Cell & Gene Therapy Stem Cell Engineering Committee review comparing outcomes, accessibility and cost of ex vivo stem cell gene therapy versus allogeneic hematopoietic stem cell transplantation.

    Leonard A, Bertaina A, Bonfim C, et al.

    Cytotherapy 2022; (24(3)):249-261 doi:10.1016/j.jcyt.2021.09.003.

    PMID: 34879990
  4. 4

    Clinical data comparison for FDA-approved gene therapies in sickle cell disease.

    Leonard A, Kanter J

    Experimental biology and medicine (Maywood, N.J.) 2025; (250()):10806 doi:10.3389/ebm.2025.10806.

    PMID: 41439171
  5. 5

    Choice of Donor Source and Conditioning Regimen for Hematopoietic Stem Cell Transplantation in Sickle Cell Disease.

    Limerick E, Fitzhugh C

    Journal of clinical medicine 2019; (8(11)) doi:10.3390/jcm8111997.

    PMID: 31731790
  6. 6

    Hematopoietic stem cell transplantation for sickle cell disease: The changing landscape.

    Kassim AA, Sharma D

    Hematology/oncology and stem cell therapy 2017; (10(4)):259-266 doi:10.1016/j.hemonc.2017.05.008.

    PMID: 28641096
  7. 7

    Encouraging Outcomes of Hematopoeitic Stem Cell Transplantation in Pediatric Sickle Cell Disease- A Decade-Long Experience from the Developing World.

    Bhayana S, Chakaroborty S, Nathany S, et al.

    Hemoglobin 2025; (49(5)):317-322 doi:10.1080/03630269.2025.2568129.

    PMID: 41047333
  8. 8

    Matched sibling donor stem cell transplantation for sickle cell disease: Results from the Spanish group for bone marrow transplantation in children.

    Benítez-Carabante MI, Beléndez C, González-Vicent M, et al.

    European journal of haematology 2021; (106(3)):408-416 doi:10.1111/ejh.13566.

    PMID: 33296531
  9. 9

    Dermatologic complications in pediatric patients after hematopoietic stem cell transplantation for sickle cell disease.

    Dignum T, Burroughs L, Mallhi K, Brandling-Bennett HA

    Pediatric dermatology 2024; (41(1)):61-65 doi:10.1111/pde.15471.

    PMID: 37965881
  10. 10

    Editorial: First Regulatory Approvals for CRISPR-Cas9 Therapeutic Gene Editing for Sickle Cell Disease and Transfusion-Dependent β-Thalassemia.

    Parums DV

    Medical science monitor : international medical journal of experimental and clinical research 2024; (30()):e944204 doi:10.12659/MSM.944204.

    PMID: 38425279
  11. 11

    Sickle cell disease gene therapy drug expenses and reimbursement: a litmus test for commercial pricing strategy and patient access for curative therapies.

    Grilley BJ, Hume A, Galipeau J

    Cytotherapy 2025; (27(5)):567-570 doi:10.1016/j.jcyt.2025.01.008.

    PMID: 39891631
  12. 12

    Gene therapy for sickle cell disease.

    Leonard A, Tisdale JF

    Hematology. American Society of Hematology. Education Program 2023; (2023(1)):542-547 doi:10.1182/hematology.2023000487.

    PMID: 38066927
  13. 13

    Gene Therapies for Hemoglobinopathies: Efficacy, Cell Collection & Transfusion Support.

    Inam Z, Han H, Webb J, Delaney M

    Transfusion medicine reviews 2025; (39(4)):150930 doi:10.1016/j.tmrv.2025.150930.

    PMID: 41223813
  14. 14

    Revolutionary breakthrough: FDA approves CASGEVY, the first CRISPR/Cas9 gene therapy for sickle cell disease.

    Singh A, Irfan H, Fatima E, et al.

    Annals of medicine and surgery (2012) 2024; (86(8)):4555-4559 doi:10.1097/MS9.0000000000002146.

    PMID: 39118728
  15. 15

    Exagamglogene Autotemcel for Severe Sickle Cell Disease.

    Frangoul H, Locatelli F, Sharma A, et al.

    The New England journal of medicine 2024; (390(18)):1649-1662 doi:10.1056/NEJMoa2309676.

    PMID: 38661449
  16. 16

    CRISPR/Cas9 System as a Promising Therapy in Thalassemia and Sickle Cell Disease: A Systematic Review of Clinical Trials.

    Ahmed R, Alghamdi WN, Alharbi FR, et al.

    Molecular biotechnology 2026; (68(1)):23-32 doi:10.1007/s12033-025-01368-x.

    PMID: 39794549
  17. 17

    Infrequent Resolution of Vaso-Occlusive Crises in Routine Clinical Care Among Patients Mimicking the Exa-Cel Trial Population: A Cohort Study of Medicaid Enrollees.

    Mahesri M, Lee SB, Levin R, et al.

    Clinical pharmacology and therapeutics 2024; (116(6)):1572-1579 doi:10.1002/cpt.3449.

    PMID: 39328080
  18. 18

    Acute Myeloid Leukemia Case after Gene Therapy for Sickle Cell Disease.

    Goyal S, Tisdale J, Schmidt M, et al.

    The New England journal of medicine 2022; (386(2)):138-147 doi:10.1056/NEJMoa2109167.

    PMID: 34898140
  19. 19

    Lovo-cel gene therapy for sickle cell disease: Treatment process evolution and outcomes in the initial groups of the HGB-206 study.

    Kanter J, Thompson AA, Pierciey FJ, et al.

    American journal of hematology 2023; (98(1)):11-22 doi:10.1002/ajh.26741.

    PMID: 36161320
  20. 20

    Biologic and Clinical Efficacy of LentiGlobin for Sickle Cell Disease.

    Kanter J, Walters MC, Krishnamurti L, et al.

    The New England journal of medicine 2022; (386(7)):617-628 doi:10.1056/NEJMoa2117175.

    PMID: 34898139
  21. 21

    Leukemia after gene therapy for sickle cell disease: insertional mutagenesis, busulfan, both, or neither.

    Jones RJ, DeBaun MR

    Blood 2021; (138(11)):942-947 doi:10.1182/blood.2021011488.

    PMID: 34115136
  22. 22

    Best Practices in Gene Therapy for Sickle Cell Disease and Transfusion-dependent β-Thalassemia.

    Frangoul H, Stults A, Bruce K, et al.

    Transplantation and cellular therapy 2025; (31(6)):352.e1-352.e10 doi:10.1016/j.jtct.2025.02.025.

    PMID: 40058646
  23. 23

    Gene therapy for hemoglobinopathies.

    Tanhehco YC

    Transfusion and apheresis science : official journal of the World Apheresis Association : official journal of the European Society for Haemapheresis 2021; (60(1)):103061 doi:10.1016/j.transci.2021.103061.

    PMID: 33461919
  24. 24

    Live birth after autograft of ovarian tissue cryopreserved during childhood.

    Demeestere I, Simon P, Dedeken L, et al.

    Human reproduction (Oxford, England) 2015; (30(9)):2107-9 doi:10.1093/humrep/dev128.

    PMID: 26062556
  25. 25

    [Therapeutic approaches in sickle cell disease].

    Joseph L, Arlet JB, Bernaudin F, Dhédin N

    La Revue du praticien 2023; (73(5)):535-539.

    PMID: 37309792
  26. 26

    Current Status of Clinical Gene Therapy for Hemophilia and Globin Disorders.

    Winkler R, Herath I, Kaczmarek R, et al.

    Journal of blood medicine 2026; (17()):576017 doi:10.2147/JBM.S576017.

    PMID: 41773269
  27. 27

    Treating Sickle Cell Disease: Gene Therapy Approaches.

    Cavazzana M, Corsia A, Brusson M, et al.

    Annual review of pharmacology and toxicology 2025; (65(1)):397-413 doi:10.1146/annurev-pharmtox-022124-022000.

    PMID: 39259977
  28. 28

    Innovative Payment Models for Sickle-Cell Disease Gene Therapies in Medicaid: Leveraging Real-World Data and Insights from CMMI's Gene Therapy Access Model.

    Zemplenyi A, Leonard J, Wright GC, et al.

    PharmacoEconomics 2025; (43(5)):583-594 doi:10.1007/s40273-025-01474-3.

    PMID: 39982606
  29. 29

    The racial politics of visibility and equity in genome-editing therapies for sickle cell disease.

    Molina SJ, Creary M

    Social science & medicine (1982) 2025; (383()):118452 doi:10.1016/j.socscimed.2025.118452.

    PMID: 40768953
  30. 30

    Curative Approach to the Treatment of Beta-Thalassemia and Sickle Cell Disease with Hematopoietic Stem Cell Transplantation.

    Testa U, Castelli G, Pelosi E

    Journal of clinical medicine 2026; (15(4)) doi:10.3390/jcm15041379.

    PMID: 41753067

This page explains curative treatment options for sickle cell disease for educational purposes only. Always discuss the specific risks, benefits, and eligibility requirements of stem cell transplants and gene therapy with your hematologist.

Stay up to date

Get notified when new research about Sickle cell anemia is published.

No spam. Unsubscribe anytime.